65,437 trials
Diabetes Mellitus, Type II
Primary: Treatment Failure (Loss of Glycemic Control) — 120; 90; 109; 112 participants
Type 2 Diabetes Mellitus
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 85.5; 83.6; 70.8; 80.3 percentage of participants
Neuropathic Pain
Primary: Cmax - Maximum Observed Plasma Concentration — 1091; 1224 ng/mL
Stress Disorders, Post-Traumatic · Depressive Symptoms · Anxiety Symptoms
Primary: PTSD Checklist (PCL) — 65.53; 65.40; 51.39; 57.89 units on a scale
Nicotine Dependence
Primary: Smoking Topography: Total Puff Volume — 523.4; 684.6 milliliters
Healthy
Primary: Intraclass Correlation Coefficient Between Physician Resident and Attending Physician. — .69 Intraclass Correlation Coefficient
Congenital Disorders
Primary: Change in Flow Mediated Dilation — 5.5 Percentage of brachial artery diameter
Chronic Disease · Hepatitis C · Stress Disorders, Post-Traumatic
Primary: Hepatitis C Virus Knowledge Questionnaire — 37.88; 40.50; 35.80; 45.38 units on a scale
Amputation
Primary: Obstacle Course Completion Time — 425; 444; 419; 287 seconds
Smoking Cessation
Primary: Participants Self-reporting Abstinence During 6 Weeks Post Quit — 16; 13 participants
Prevent Child Maltreatment
Primary: Parenting Style — 2.65; 2.61; 2.09; 2.21 scores on a scale
Ovarian Cancer · Epithelial Ovarian Cancer · Fallopian Tube Cancer
Primary: Maximum Tolerable Dose (MTD) Belinostat, Part A, — 1000 mg/m2
Asthma
Primary: Pediatric Asthma Quality of Life Questionnaire (PAQLQ) — 140.30; 125.12; 138.11 units on a scale
Skin Diseases · Telemedicine · Quality of Life
Primary: Skindex-16 Change Scores Between Baseline to Month 9 - Composite Score — -12.0; -13.2 units on a scale — p=0.66
Major Depressive Disorder
Primary: Hamilton Depression (HAM-D) and Anxiety (HAM-A) Rating Scales — 20.07; 21.36; 1; 14.07 units on a scale